2017版ELN急性髓系白血病遗传风险分层的验证与优化
在1116例接受诱导化疗的新诊断AML患者中验证2017版ELN遗传风险分层,发现该分层可显著区分不同风险组的5年总生存率,且双等位CEBPA突变或inv(16)预后尤佳,TP53突变伴复杂核型预后极差,DNMT3A突变在各风险组内均与较差OS相关。
要点
- ELN-2017在广泛年龄范围验证了其预后区分能力。
- 双等位CEBPA突变或inv(16)患者预后尤其良好。
- TP53突变伴复杂核型患者预后尤其差。
核心结论
- ELN-2017遗传风险分层在接受诱导化疗的AML患者中具有预后意义,但可进一步优化。
研究设计与样本
- 研究纳入1116例新诊断AML患者(年龄18-86岁),均接受诱导化疗。
主要发现
- 在771例非遗传学筛选患者中,ELN-2017将26.5%的患者重新分入更有利或更不利风险组。
- <60岁患者(599例)5年OS:favorable 64%、intermediate 42%、adverse 20%。
- ≥60岁患者(517例)5年OS:favorable 37%、intermediate 16%、adverse 6%。
- 双等位CEBPA突变或inv(16)预后尤佳,TP53突变伴复杂核型预后尤差,DNMT3A突变在各ELN-2017风险组内均与较差OS相关。
临床怎么用
- 可将ELN-2017用于接受诱导化疗的AML患者风险分层咨询。
- 对双等位CEBPA突变或inv(16)患者可考虑更积极预后预期。
- 对TP53突变伴复杂核型患者需警惕极差预后。
- DNMT3A突变可在各风险组内提示更差生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia have been widely adopted, but have not yet been validated in large cohorts of AML patients. We studied 1116 newly diagnosed AML patients (age range, 18-86 years) who had received induction chemotherapy. Among 771 patients not selected by genetics, the ELN-2017 classification re-assigned 26.5% of patients into a more favorable or, more commonly, a more adverse-risk group compared with the ELN-2010 recommendations. Forty percent of the cohort, and 51% of patients ≥60 years, were classified as adverse-risk by ELN-2017. In 599 patients <60 years, estimated 5-year overall survival (OS) was 64% for ELN-2017 favorable, 42% for intermediate-risk and 20% for adverse-risk patients. Among 517 patients aged ≥60 years, corresponding 5-year OS rates were 37, 16, and 6%. Patients with biallelic CEBPA mutations or inv(16) had particularly favorable outcomes, while patients with mutated TP53 and a complex karyotype had especially poor prognosis. DNMT3A mutations associated with inferior OS within each ELN-2017 risk group. Our results validate the prognostic significance of the revised ELN-2017 risk classification in AML patients receiving induction chemotherapy across a broad age range. Further refinement of the ELN-2017 risk classification is possible.
引用
- Herold T, Rothenberg-Thurley M, Grunwald VV, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020. PMID: 32231256. doi:10.1038/s41375-020-0806-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。